Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exatecan in Advanced Soft Tissue Sarcoma
NCT00041236Phase 2Completed
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- May 2002
- Primary completion
- Dec 2004
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, open-label, single-arm trial of exatecan in soft tissue sarcoma (STS), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: Objective Response Rate. Started May 2002; status: completed.
02
Drugs
exatecan
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT00041236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00041236.